Literature DB >> 33489333

Diagnostic Performance of a Novel Noninvasive Workup in the Setting of Dry Eye Disease.

Luca Vigo1, Marco Pellegrini2, Federico Bernabei2, Francesco Carones1, Vincenzo Scorcia3, Giuseppe Giannaccare3.   

Abstract

PURPOSE: To evaluate the diagnostic performance of a novel noninvasive automated workup employed for the diagnosis of dry eye disease (DED).
METHODS: One hundred patients with mild to moderate DED and 100 matched control subjects were enrolled in this cross-sectional study. Ocular surface examinations were carried out by means of IDRA Plus (SBM Sistemi, Turin, Italy), which allows the automated evaluation of noninvasive breakup time (NIBUT), lipid layer thickness (LLT), tear meniscus height (TMH), infrared meibography for the measurement of meibomian gland loss (MGL), and blinking analysis. Continuous variables were compared between patients with DED and controls by using the Mann-Whitney U test. The area under the curve (AUC) of receiver operating characteristic curves was calculated. The correlations between ocular surface parameters were evaluated with Pearson correlation analysis.
RESULTS: Patients with DED showed significantly lower values of NIBUT, LLT, and TMH compared to controls (6.9 ± 2.5 vs 10.4 ± 2.4 s, P < 0.001; 64.6 ± 20.3 vs 73.4 ± 21.9 nm, P = 0.003; 0.231 ± 0.115 vs 0.289 ± 0.164, P = 0.012, respectively). Conversely, no significant differences were observed for MGL and blinking analysis (both P > 0.05). NIBUT had the highest diagnostic power (AUC = 0.841, sensitivity = 0.89, and specificity = 0.69), followed by LLT (AUC = 0.621, sensitivity = 0.89, and specificity = 0.55), TMH (AUC = 0.606, sensitivity = 0.57, and specificity = 0.63), blink analysis (AUC = 0.533, sensitivity = 0.48, and specificity = 0.59), and MGL (AUC = 0.531, sensitivity = 0.54, and specificity = 0.48). In patients with DED, NIBUT showed a significant correlation with TMH (R = 0.347, P = 0.002) and blinking analysis (R = 0.356, P < 0.001), while blinking analysis was negatively correlated with MGL (R = -0.315, P = 0.008).
CONCLUSIONS: The automated noninvasive workup validated in this study may be a useful tool for reaching a noninvasive diagnosis of DED with a good performance, especially for NIBUT.
Copyright © 2020 Luca Vigo et al.

Entities:  

Year:  2020        PMID: 33489333      PMCID: PMC7803097          DOI: 10.1155/2020/5804123

Source DB:  PubMed          Journal:  J Ophthalmol        ISSN: 2090-004X            Impact factor:   1.909


  25 in total

Review 1.  TFOS DEWS II Definition and Classification Report.

Authors:  Jennifer P Craig; Kelly K Nichols; Esen K Akpek; Barbara Caffery; Harminder S Dua; Choun-Ki Joo; Zuguo Liu; J Daniel Nelson; Jason J Nichols; Kazuo Tsubota; Fiona Stapleton
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

2.  Morphological evaluation of meibomian glands using noncontact infrared meibography.

Authors:  Yumiko Ban; Seika Shimazaki-Den; Kazuo Tsubota; Jun Shimazaki
Journal:  Ocul Surf       Date:  2012-10-16       Impact factor: 5.033

3.  A non-invasive instrument for clinical assessment of the pre-corneal tear film stability.

Authors:  L S Mengher; A J Bron; S R Tonge; D J Gilbert
Journal:  Curr Eye Res       Date:  1985-01       Impact factor: 2.424

Review 4.  Blink: Characteristics, Controls, and Relation to Dry Eyes.

Authors:  John D Rodriguez; Keith J Lane; George W Ousler; Endri Angjeli; Lisa M Smith; Mark B Abelson
Journal:  Curr Eye Res       Date:  2017-10-18       Impact factor: 2.424

5.  Ocular Surface Workup With Automated Noninvasive Measurements for the Diagnosis of Meibomian Gland Dysfunction.

Authors:  Giuseppe Giannaccare; Luca Vigo; Marco Pellegrini; Stefano Sebastiani; Francesco Carones
Journal:  Cornea       Date:  2018-06       Impact factor: 2.651

6.  Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications.

Authors:  Benjamin D Sullivan; Leslie A Crews; Elisabeth M Messmer; Gary N Foulks; Kelly K Nichols; Philipp Baenninger; Gerd Geerling; Francisco Figueiredo; Michael A Lemp
Journal:  Acta Ophthalmol       Date:  2012-12-28       Impact factor: 3.761

7.  Evaluation of lipid layer thickness measurement of the tear film as a diagnostic tool for Meibomian gland dysfunction.

Authors:  David Finis; Nadja Pischel; Stefan Schrader; Gerd Geerling
Journal:  Cornea       Date:  2013-12       Impact factor: 2.651

8.  Concordance between common dry eye diagnostic tests.

Authors:  J E Moore; J E Graham; E A Goodall; D A Dartt; A Leccisotti; V E McGilligan; T C B Moore
Journal:  Br J Ophthalmol       Date:  2008-09-09       Impact factor: 4.638

9.  Effect of non-invasive tear stability assessment on tear meniscus height.

Authors:  Shizuka Koh; Chikako Ikeda; Shinya Watanabe; Yoshinori Oie; Takeshi Soma; Hitoshi Watanabe; Naoyuki Maeda; Kohji Nishida
Journal:  Acta Ophthalmol       Date:  2014-10-12       Impact factor: 3.761

10.  Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light.

Authors:  Luca Vigo; Leonardo Taroni; Federico Bernabei; Marco Pellegrini; Stefano Sebastiani; Andrea Mercanti; Nicola Di Stefano; Vincenzo Scorcia; Francesco Carones; Giuseppe Giannaccare
Journal:  Diagnostics (Basel)       Date:  2019-10-13
View more
  9 in total

1.  Special Issue "Diagnosis and Management of Dry Eye Disease and Ocular Surface Inflammation".

Authors:  Giuseppe Giannaccare; Antonio Di Zazzo
Journal:  Medicina (Kaunas)       Date:  2022-06-05       Impact factor: 2.948

2.  Lipid, Aqueous and Mucin Tear Film Layer Stability and Permanence within 0.15% Liposome Crosslinked Hyaluronic Acid versus 0.15% Non-Crosslinked Hyaluronic Acid Measured with a Novel Non-Invasive Ocular Surface Analyzer.

Authors:  José-María Sánchez-González; Concepción De-Hita-Cantalejo; Concepción Martínez-Lara; María Carmen Sánchez-González
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

3.  Short-Term Effects of a Novel Eye Mask Producing Heat and Vibration for the Treatment of Meibomian Gland Dysfunction: A Pilot Study.

Authors:  Luca Vigo; Marco Pellegrini; Francesco Carones; Vincenzo Scorcia; Giuseppe Giannaccare
Journal:  J Ophthalmol       Date:  2021-08-17       Impact factor: 1.909

4.  Dry eye, its clinical subtypes and associated factors in healthy pregnancy: A cross-sectional study.

Authors:  Kofi Asiedu; Samuel Kyei; Madison Adanusa; Richard Kobina Dadzie Ephraim; Stephen Animful; Stephen Karim Ali-Baya; Belinda Akorsah; Mabel Antwiwaa Sekyere
Journal:  PLoS One       Date:  2021-10-07       Impact factor: 3.240

5.  Advances in Dry Eye Disease Examination Techniques.

Authors:  Yaying Wu; Chunyang Wang; Xin Wang; Yujie Mou; Kelan Yuan; Xiaodan Huang; Xiuming Jin
Journal:  Front Med (Lausanne)       Date:  2022-01-25

6.  Evaluation of the Ocular Surface and Meibomian Gland in Obstructive Sleep Apnea Hypopnea Syndrome.

Authors:  Shaohua Liu; Shisheng Li; Mengmeng Li; Shiying Zeng; Baihua Chen; Liwei Zhang
Journal:  Front Med (Lausanne)       Date:  2022-02-09

7.  Effects of a New Formulation of Multiple-Action Tear Substitute on Objective Ocular Surface Parameters and Ocular Discomfort Symptoms in Patients with Dry Eye Disease.

Authors:  Luca Vigo; Giuseppe Giannaccare; Carlotta Senni; Marco Pellegrini; Aldo Vagge; Lorenzo Ferro Desideri; Francesco Carones; Vincenzo Scorcia
Journal:  Ophthalmol Ther       Date:  2022-05-14

8.  Dry eye disease and tear film assessment through a novel non-invasive ocular surface analyzer: The OSA protocol.

Authors:  María Carmen Sánchez-González; Raúl Capote-Puente; Marta-C García-Romera; Concepción De-Hita-Cantalejo; María-José Bautista-Llamas; Carmen Silva-Viguera; José-María Sánchez-González
Journal:  Front Med (Lausanne)       Date:  2022-08-10

9.  Diurnal changes of noninvasive parameters of ocular surface in healthy subjects before and after continuous face mask wearing during the COVID-19 pandemic.

Authors:  Giuseppe Giannaccare; Marco Pellegrini; Massimiliano Borselli; Carlotta Senni; Angela Bruno; Vincenzo Scorcia
Journal:  Sci Rep       Date:  2022-07-29       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.